Armistice Capital reports 9.99% of Imunon
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G disclosing beneficial ownership of 396,718 shares of Imunon, Inc. common stock, representing 9.99% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G disclosing beneficial ownership of 396,718 shares of Imunon, Inc. common stock, representing 9.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power via an Investment Management Agreement.
Insights
Armistice reports a near-10% position with shared control via an investment manager.
Armistice Capital is disclosed as the investment manager for the Master Fund and is reported to exercise voting and investment power over 396,718 shares of common stock (9.99%). The Master Fund is identified as the direct holder.
The filing clarifies that the Master Fund "specifically disclaims beneficial ownership" due to its inability to vote or dispose of the shares under the Investment Management Agreement; cash-flow treatment and any planned disposition activity are not included in the excerpt.
Key Figures
Key Terms
Investment Management Agreement regulatory
Beneficial ownership regulatory
Schedule 13G/A regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Armistice Capital report in IMNN?
Does the Master Fund claim beneficial ownership in the filing?
When was the Schedule 13G/A amendment signed for IMNN?
AI-generated analysis. How Rhea-AI works. Not financial advice.